{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:28:04Z","timestamp":1792294084223,"version":"4.4.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Epstein-Barr virus (EBV) is one of the most widespread viruses in the world; more than 90% of the planet\u2019s adult population is infected. Symptomatic primary infection by this <jats:italic>Herpesviridae<\/jats:italic> corresponds to infectious mononucleosis (IM), which is generally a benign disease. While virus persistence is often asymptomatic, it is responsible for 1.5% of cancers worldwide, mainly B cell lymphomas and carcinomas. EBV may also be associated with autoimmune and\/or inflammatory diseases. However, no effective treatment or anti-EBV vaccine is currently available. Knowledge of the proteins and mechanisms involved in the different steps of the viral cycle is essential to the development of effective vaccines. The present review describes the main actors in the entry of the virus into B cells and epithelial cells, which are targets of interest in the development of prophylactic vaccines aimed at preventing viral infection. This review also summarizes the first vaccinal approaches tested in humans, all of which are based on the gp350\/220 glycoprotein; while they have reduced the risk of IM, they have yet to prevent EBV infection. The main proteins involved in the EBV latency cycle and some of the proteins involved in the lytic cycle have essential roles in the oncogenesis of EBV. For that reason, these proteins are of interest for the development of therapeutic vaccines of which the objective is the stimulation of T cell immunity against EBV-associated cancers. New strategies aimed at broadening the antigenic spectrum, are currently being studied and will contribute to the targeting of the essential steps of the viral cycle, the objective being to prevent or treat the diseases associated with EBV.<\/jats:p>","DOI":"10.3389\/fmicb.2021.701611","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T06:22:40Z","timestamp":1624342960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Main Targets of Interest for the Development of a Prophylactic or Therapeutic Epstein-Barr Virus Vaccine"],"prefix":"10.3389","volume":"12","author":[{"given":"Vincent","family":"Jean-Pierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyse","family":"Buisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Germi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24050997","article-title":"Novel therapeutics for Epstein\u2013Barr Virus.","volume":"24","author":"Andrei","year":"2019","journal-title":"Molecules"},{"key":"B2","first-page":"365","article-title":"EBV and autoimmunity","author":"Ascherio","year":"2015","journal-title":"Epstein Barr Virus Volume 1 Current Topics in Microbiology and Immunology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jbspin.2017.04.011","article-title":"Epstein-Barr virus and rheumatoid arthritis.","volume":"85","author":"Balandraud","year":"2018","journal-title":"Joint Bone Spine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2014.02.005","article-title":"Progress, prospects, and problems in Epstein-Barr virus vaccine development.","volume":"6","author":"Balfour","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-7091-1818-4_8","article-title":"Adenovirus-based vectors for the development of prophylactic and therapeutic vaccines","author":"Borovjagin","year":"2014","journal-title":"Novel Technologies for Vaccine Development"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005549","article-title":"Early T cell recognition of B cells following Epstein-Barr Virus infection: identifying potential targets for prophylactic vaccination.","volume":"12","author":"Brooks","year":"2016","journal-title":"PLoS Pathog."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1305.e6","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr Virus in B cells and epithelial cells.","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/femsre\/fuz023","article-title":"Epithelial cell infection by Epstein-Barr virus.","volume":"43","author":"Chen","year":"2019","journal-title":"FEMS Microbiol. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","article-title":"Ephrin receptor A2 is a functional entry receptor for Epstein\u2013Barr virus.","volume":"3","author":"Chen","year":"2018","journal-title":"Nat. Microbiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"11686","DOI":"10.1128\/JVI.01349-14","article-title":"The Epstein-Barr virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion.","volume":"88","author":"Chen","year":"2014","journal-title":"J. Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"13214","DOI":"10.1128\/JVI.05580-11","article-title":"Fusion of Epstein-Barr virus with epithelial cells can be triggered by \u03b1v\u03b25 in addition to \u03b1v\u03b26 and \u03b1v\u03b28, and integrin binding triggers a conformational change in glycoproteins gHgL.","volume":"85","author":"Chesnokova","year":"2011","journal-title":"J. Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.virol.2016.04.002","article-title":"The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection.","volume":"494","author":"Chesnokova","year":"2016","journal-title":"Virology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-\u0394LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.","volume":"23","author":"Chia","year":"2012","journal-title":"Ann. Oncol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2014.27","article-title":"Epstein\u2013barr virus vaccines.","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"B15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/978-981-10-7230-7_22","article-title":"Vaccine development for Epstein-Barr Virus","author":"Cohen","year":"2018","journal-title":"Human Herpesviruses Advances in Experimental Medicine and Biology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention.","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nrmicro2548","article-title":"Fusing structure and function: a structural view of the herpesvirus entry machinery.","volume":"9","author":"Connolly","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030285","article-title":"Immunization with Epstein\u2013Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge.","volume":"9","author":"Cui","year":"2021","journal-title":"Vaccines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","article-title":"A novel tetrameric gp3501\u2013470 as a potential Epstein\u2013Barr virus vaccine.","volume":"31","author":"Cui","year":"2013","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/14760584.2017.1293529","article-title":"Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.","volume":"16","author":"Dasari","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"B22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/14760584.2019.1605906","article-title":"Prophylactic and therapeutic strategies for Epstein\u2013Barr virus-associated diseases: emerging strategies for clinical development.","volume":"18","author":"Dasari","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"B23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr virus infection.","volume":"102","author":"Dunmire","year":"2018","journal-title":"J. Clin. Virol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1128\/JVI.01409-07","article-title":"Phase I trial of a CD8+ T-Cell peptide epitope-based vaccine for infectious mononucleosis.","volume":"82","author":"Elliott","year":"2008","journal-title":"J. Virol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/s0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt\u2019s Lymphoma.","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet Lond. Engl."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020169","article-title":"A pentavalent Epstein-Barr virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein-Barr virus infection in immunized rabbits.","volume":"8","author":"Escalante","year":"2020","journal-title":"Vaccines"},{"key":"B27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.virol.2008.10.010","article-title":"The BDLF2 protein of Epstein\u2013Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein.","volume":"383","author":"Gore","year":"2009","journal-title":"Virology"},{"key":"B28","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen.","volume":"84","author":"Gu","year":"1995","journal-title":"Dev. Biol. Stand."},{"key":"B29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/2326-6066.CIR-14-0242","article-title":"The Epstein\u2013Barr Virus lytic protein BZLF1 as a candidate target antigen for vaccine development.","volume":"3","author":"Hartlage","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.vaccine.2016.04.012","article-title":"Identification of GLA\/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.","volume":"34","author":"Heeke","year":"2016","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2016.01.010","article-title":"gH\/gL supercomplexes at early stages of herpesvirus entry.","volume":"18","author":"Heldwein","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nm0614-571","article-title":"The cancer-virus cures.","volume":"20","author":"Holmes","year":"2014","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients.","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00367","article-title":"Role of viral and host microRNAs in immune regulation of Epstein-Barr virus-associated diseases.","volume":"11","author":"Iizasa","year":"2020","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"16286","DOI":"10.1073\/pnas.0407320101","article-title":"Proteins of purified Epstein-Barr virus.","volume":"101","author":"Johannsen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site.","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1021\/acs.nanolett.0c04687","article-title":"Immunization with a Self-assembled nanoparticle vaccine elicits potent neutralizing antibody responses against EBV infection.","volume":"21","author":"Kang","year":"2021","journal-title":"Nano Lett."},{"key":"B38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.semcancer.2014.01.002","article-title":"Regulation of the latent-lytic switch in Epstein\u2013Barr virus.","volume":"26","author":"Kenney","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037505","article-title":"Global and regional incidence, mortality and disability-adjusted life-years for Epstein-Barr virus-attributable malignancies, 1990\u20132017.","volume":"10","author":"Khan","year":"2020","journal-title":"BMJ Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.str.2008.12.010","article-title":"Structure of Epstein-Barr Virus glycoprotein 42 suggests a mechanism for triggering receptor-activated virus entry.","volume":"17","author":"Kirschner","year":"2009","journal-title":"Structure"},{"key":"B41","doi-asserted-by":"publisher","first-page":"11162","DOI":"10.1128\/JVI.74.23.11162-11172.2000","article-title":"Epstein-Barr virus that lacks glycoprotein gN is impaired in assembly and infection.","volume":"74","author":"Lake","year":"2000","journal-title":"J. Virol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the epstein-barr virus and risk of multiple sclerosis.","volume":"67","author":"Levin","year":"2010","journal-title":"Ann. Neurol."},{"key":"B43","first-page":"6952","article-title":"Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma.","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res."},{"key":"B44","first-page":"225","article-title":"Le virus d\u2019Epstein-Barr","author":"Lupo","year":"2019","journal-title":"Trait\u00e9 de Virologie M\u00e9dicale"},{"key":"B45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1128\/JVI.01512-10","article-title":"A new model of Epstein-Barr Virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.","volume":"85","author":"Ma","year":"2011","journal-title":"J. Virol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1128\/JVI.64.6.2545-2552.1990","article-title":"Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment.","volume":"64","author":"Mackett","year":"1990","journal-title":"J. Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"22641","DOI":"10.1073\/pnas.1011806108","article-title":"Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H\/glycoprotein L (gH\/gL) complex.","volume":"107","author":"Matsuura","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1128\/JVI.66.6.3409-3414.1992","article-title":"Epstein-Barr virus enters B cells and epithelial cells by different routes.","volume":"66","author":"Miller","year":"1992","journal-title":"J. Virol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/bs.aivir.2019.05.006","article-title":"Gammaherpesvirus entry and fusion: a tale how two human pathogenic viruses enter their host cells.","volume":"104","author":"M\u00f6hl","year":"2019","journal-title":"Adv. Virus Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1255","DOI":"10.1128\/JVI.01255-17","article-title":"Epstein-Barr Virus fusion with epithelial cells triggered by gB is restricted by a gL glycosylation site.","volume":"91","author":"M\u00f6hl","year":"2017","journal-title":"J. Virol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"286","DOI":"10.14348\/MOLCELLS.2016.0066","article-title":"Structural and mechanistic insights into the tropism of Epstein-Barr Virus.","volume":"39","author":"Mohl","year":"2016","journal-title":"Mol. Cells"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein\u2013Barr virus vaccine in healthy adults.","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jaad.2018.10.072","article-title":"Human oncoviruses: mucocutaneous manifestations, pathogenesis, therapeutics, and prevention.","volume":"81","author":"Mui","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein\u2013Barr virus-associated oncogenesis.","volume":"17","author":"M\u00fcnz","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061400","article-title":"Redirecting T cells against Epstein\u2013Barr Virus Infection and associated oncogenesis.","volume":"9","author":"M\u00fcnz","year":"2020","journal-title":"Cells"},{"key":"B56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4899-0036-4_10","article-title":"Epstein-Barr virus","author":"Niederman","year":"1997","journal-title":"Viral Infections of Humans: Epidemiology and Control"},{"key":"B57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s004280050402","article-title":"The Epstein-Barr virus: a group 1 carcinogen?","volume":"435","author":"Niedobitek","year":"1999","journal-title":"Virchows Arch."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/JVI.02533-12","article-title":"An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.","volume":"87","author":"Pavlova","year":"2013","journal-title":"J. Virol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092565","article-title":"Targeted therapies for Epstein-Barr Virus-associated lymphomas.","volume":"12","author":"Pei","year":"2020","journal-title":"Cancers"},{"key":"B60","doi-asserted-by":"publisher","first-page":"19255","DOI":"10.18632\/oncotarget.13770","article-title":"Novel Epstein-Barr virus-like particles incorporating gH\/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.","volume":"8","author":"Perez","year":"2017","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A Phase I trial of Epstein-Barr Virus Gp350 vaccine for children with chronic kidney disease awaiting transplantation.","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"key":"B62","first-page":"655","article-title":"Epstein-Barr Virus","author":"Rickinson","year":"2013","journal-title":"Fields Virology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1172\/JCI125364","article-title":"Heterologous prime-boost vaccination protects against EBV antigen\u2013expressing lymphomas.","volume":"129","author":"R\u00fchl","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1007\/s00018-020-03538-3","article-title":"Vaccination against the Epstein\u2013Barr virus.","volume":"77","author":"R\u00fchl","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13557","article-title":"Structural basis for Epstein\u2013Barr virus host cell tropism mediated by gp42 and gHgL entry glycoproteins.","volume":"7","author":"Sathiyamoorthy","year":"2016","journal-title":"Nat. Commun."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004309","article-title":"Assembly and architecture of the EBV B cell entry triggering complex.","volume":"10","author":"Sathiyamoorthy","year":"2014","journal-title":"PLoS Pathog."},{"key":"B67","doi-asserted-by":"publisher","first-page":"E8703","DOI":"10.1073\/pnas.1704661114","article-title":"Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies.","volume":"114","author":"Sathiyamoorthy","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein\u2013Barr virus-associated lymphomas.","volume":"372","author":"Shannon-Lowe","year":"2017","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","article-title":"The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a Phase I clinical trial and two-year follow-up.","volume":"64","author":"Si","year":"2016","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"B70","doi-asserted-by":"publisher","first-page":"799.e9","DOI":"10.1016\/j.immuni.2018.03.026","article-title":"An antibody targeting the fusion machinery neutralizes dual-tropic infection and defines a site of vulnerability on Epstein-Barr Virus.","volume":"48","author":"Snijder","year":"2018","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.","volume":"196","author":"Sokal","year":"2007","journal-title":"J. Infect. Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/jop.13036","article-title":"EBV and CMV viral load in rheumatoid arthritis and their role in associated Sj\u00f6gren\u2019s syndrome.","volume":"49","author":"Sorgato","year":"2020","journal-title":"J. Oral Pathol. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","article-title":"Treatment of nasopharyngeal carcinoma with Epstein-Barr virus\u2013specific T lymphocytes.","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3892\/or.2015.4401","article-title":"Expression of LMP and EBNA genes in Epstein-Barr virus-associated lymphomas in Hu-PBL\/SCID mice.","volume":"35","author":"Tang","year":"2016","journal-title":"Oncol. Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1084\/jem.20161846","article-title":"Human immunity against EBV\u2014lessons from the clinic.","volume":"214","author":"Tangye","year":"2017","journal-title":"J. Exp. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual Stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.","volume":"78","author":"Taylor","year":"2004","journal-title":"J. Virol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a Phase I trial in UK patients with EBV-positive cancer.","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00104","article-title":"Progress in EBV Vaccines.","volume":"9","author":"van Zyl","year":"2019","journal-title":"Front. Oncol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007464","article-title":"Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice.","volume":"14","author":"van Zyl","year":"2018","journal-title":"PLoS Pathog."},{"key":"B80","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1128\/JVI.77.11.6546-6550.2003","article-title":"Multiple Epstein-Barr virus infections in healthy individuals.","volume":"77","author":"Walling","year":"2003","journal-title":"J. Virol."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7240","article-title":"Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells.","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"B82","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.7150\/thno.42494","article-title":"A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00932","article-title":"Immunization with Fc-based recombinant Epstein\u2013Barr virus gp350 elicits potent neutralizing humoral immune response in a BALB\/c mice model.","volume":"9","author":"Zhao","year":"2018","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.701611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T06:22:51Z","timestamp":1624342971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.701611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":83,"alternative-id":["10.3389\/fmicb.2021.701611"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.701611","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"article-number":"701611"}}